Marisa Chang
Neurology · Los Angeles, CANPI 1730348269
Payments from drug & device makers
Across 1,171 payments — averaging $26.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- International Rehabilitative Sciences, Inc$5K
- AbbVie$4K
- Lundbeck LLC$2K
- Teva Pharmaceuticals USA, Inc.$1K
- UCB, Inc.$1K
- Lilly USA, LLC$1K
- plus $15K from 54 others
What the payments were for
- Speaking & faculty fees$690%
- Food & beverage$25,42083%
- Education$3421%
- Other$4,76816%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RS-4i Plus with Intersperse$4,768
- RS-LBG, RS-FBG$4,768
- Inspire$200
- Zilbrysq$125
- AJOVY$110
How this compares
$30,599 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 13 | $181,303 |
| Emgality PenGalcanezumab-Gnlm | 49 | $38,201 |
| Nurtec OdtRimegepant Sulfate | 25 | $37,034 |
| BriviactBrivaracetam | 12 | $15,634 |
| UbrelvyUbrogepant | 16 | $15,553 |
| QuviviqDaridorexant Hcl | 25 | $13,339 |
| Memantine Hcl ErMemantine Hcl | 14 | $2,584 |
| Memantine Hcl | 96 | $2,198 |
| Oxcarbazepine | 21 | $1,696 |
| Pregabalin | 19 | $1,434 |
| Gabapentin | 79 | $1,432 |
| Duloxetine Hcl | 112 | $1,349 |
| Nortriptyline Hcl | 39 | $1,098 |
| RizatriptanRizatriptan Benzoate | 54 | $879 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $833 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $1,043 | $37,03425 claims |
| UCB, Inc.Briviact | $1,252 | $15,63412 claims |
| AbbVieUbrelvy | $4,428 | $15,55316 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $77 | $13,33925 claims |
| Upsher-smith Laboratories LLCTopiramate | $489 | $55832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.
Other neurology in Los Angeles
- Timothy CloughesyLos Angeles$33.1M
- Perry ShiehLos Angeles$8.2M
- Jeffrey SaverLos Angeles$2.9M
- David PiccioniLos Angeles$2.9M
- David LiebeskindLos Angeles$2.7M
- Michele TagliatiLos Angeles$2.5M
- Jennifer HuiLos Angeles$2.4M
- Susan PerlmanLos Angeles$2.2M
- Jeffrey CummingsLos Angeles$2M
- Bryan SpannLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.